Press Release
Shire plc announces refinancing of bank facilities
2 May 2007
Shire plc announces refinancing of bank facilities connected with the recent acquisition of New River through the launch of US,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only.
Basingstoke, UK – 2 May 2007 – Shire plc ("Shire" or the “Company”) (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it intends to make an offering of US,000 million principal amount of Convertible Bonds (“Bonds”) due 2014 to international institutional investors outside the United States that are non-US persons. The proceeds of the offering will provide refinancing on attractive terms for part of the bank facilities put in place for the recent acquisition of New River Pharmaceuticals Inc.
To view the full announcement please visit our website http://www.shire.com and go to the Latest News.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
